Koopman W J
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham 35294-0006.
Semin Arthritis Rheum. 1994 Jun;23(6 Suppl 2):50-8. doi: 10.1016/0049-0172(94)90085-x.
The development of highly effective biological therapies directed against T cells in several animal models of autoimmune disease has prompted trials of similar approaches in rheumatoid arthritis (RA). However, it is unlikely that these approaches will abrogate long-standing disease. Indeed, considerable evidence indicates that although T cells likely play a critical role in induction of RA, non-T-cell-dependent pathways become increasingly dominant as the disease progresses. According to this model, specific T-cell therapies are likely to be most effective in early disease, whereas individualized combinations of biologics targeted against pathways dominating in the recipient's synovium are more likely to be efficacious in established disease.
在几种自身免疫性疾病动物模型中，针对T细胞的高效生物疗法的发展促使人们在类风湿关节炎（RA）中尝试类似方法。然而，这些方法不太可能消除长期存在的疾病。事实上，大量证据表明，虽然T细胞可能在RA的诱发中起关键作用，但随着疾病进展，非T细胞依赖性途径变得越来越占主导地位。根据这个模型，特异性T细胞疗法在疾病早期可能最有效，而针对受体滑膜中占主导地位途径的生物制剂个体化组合在已确诊疾病中更可能有效。
